Otolaryngology Doctors in Eglin Afb, FL Accepting Medicare

4 Otolaryngology doctors found. Showing 1 - 4

Dr. Brian Andrew Moore, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 307 Boatner Rd, Suite 114, Eglin Afb, FL 32542 Phone: 850-883-8264    Fax: 850-883-8253

Dr. Gale Timothy Tuper Jr., MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 307 Boatner Rd Ste 114, 96th Medical Group, Eglin Afb, FL 32542 Phone: 850-883-8264

Dr. Mark A Criswell, M.D., F.A.C.S. Otolaryngology Medicare: Medicare Enrolled Practice Location: 307 Boatner Rd Ste 114, Eglin Afb, FL 32542 Phone: 850-883-8264

Nathanael W Nickel, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 307 Boatner Rd Ste 114, Eglin Afb, FL 32542 Phone: 850-883-8600

News Archive

Short coverage lapses limit children's access to health care services

Children's access to health care suffers when they spend any time-even a few months-without health care coverage, according to a new study appearing in the February 2009 issue of Medical Care Research and Review.

University of Montreal scientists discover free radical mechanism to viral invasion

Canadian researchers have discovered a new way the body combats respiratory viral infections. In the prestigious journal PLoS Pathogens, scientists from the University of Montreal and the University of Montreal Hospital Research Center explain how the NOX2 molecule, an enzyme that generates a burst of highly reactive oxygen derivatives (or free radicals), activates defense genes and molecules when viruses invade lung cells.

Study reveals direct correlation between negative thinking about pain and poor sleep

Chronic pain sufferers who learn to dwell less on their ailments may sleep better and experience less day-to-day pain, according to results of research conducted on 214 people with chronic face and jaw pain.

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.

Alzheimer's disease risk differs between the sexes

The risks of developing Alzheimer's disease differ between the sexes, with stroke in men, and depression in women, critical factors, suggests research published ahead of print in the Journal of Neurology Neurosurgery and Psychiatry.

Read more Medical News

› Verified 6 days ago